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A B S T R A C T
In pharmaceutical technology, lipids and polymers are considered pillar excipients for the fabrication of most
dosage forms, irrespective of the administration route. They play various roles ranging from support vehicles to
release rate modiﬁers, stabilizers, solubilizers, permeation enhancers and transfection agents. Focusing on se-
lected applications, which were discussed at the Annual Scientiﬁc Meeting of the Gattefossé Foundation 2018,
this manuscript recapitulates the fundamental roles of these two important classes of excipients, either employed
alone or in combination, and provides insight on their functional properties in various types of drug formula-
tions. Emphasis is placed on oral formulations for the administration of active pharmaceutical ingredients with
low aqueous solubilities or poor permeation properties. Additionally, this review article covers the use of lipids
and polymers in the design of colloidal injectable delivery systems, and as substrates in additive manufacturing
technologies for the production of tailor-made dosage forms.
1. Introduction
Lipids and polymers have always been essential components of
pharmaceutical dosage forms. Early civilizations already described the
preparation of pills and ointments made with these excipients, in-
corporating for example gums and waxes in their medicinal mixtures
(Allen and Ansel, 2013). The Galen’s cerate (AD 200), better known
today as cold cream, is a classic example of a lipid-based formulation as
it consists of a stabilized dispersion of water in a lipidic continuous
phase (Pastore, et al., 2015). In those early days and following cen-
turies, lipids and polymers were obtained from natural sources, and
mainly served as support materials or bulking agents for the active
compound. With the advent of modern medicine, the progress in
chemistry and the industrialization of the manufacturing processes,
excipients evolved and gained in purity, becoming exploited for diverse
functionalities. In the 19th century, more puriﬁed polymeric materials
such as gelatin began to be used for the preparation of capsules and
tablets (Cowen and Helfand, 1990). Today, drug formulators have at
their disposal a wide range of natural, semi-synthetic or completely
man-made lipids and polymers that are produced in various pharma-
ceutical grades, allowing their administration via diﬀerent routes (oral,
topical, parenteral or rectal) (Allen and Ansel, 2013).
Despite considerable structural diﬀerences, lipids and polymers
often fulﬁll similar functions. They may be used to prepare dispersion/
solubilization matrices, controlled release formulations and colloidal
targeted systems (nanoparticles and vesicles), and act as permeation
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enhancers (Aulton and Taylor, 2018). Nevertheless, important diﬀer-
ences (e.g. mechanical properties, melting point, biodegradability, so-
lubility, etc.) make them suitable for achieving distinct tasks. For ex-
ample, poly(ethylene glycol) (PEG) is employed to produce water-
soluble suppositories, whereas fatty vehicles are used to manufacture
suppositories that melt at body temperature (Aulton and Taylor, 2018).
Lipids and polymers can also have complementary roles. This is com-
monly exploited in modern pharmaceutical technology. For instance,
lipids are added as antifriction agents to polymeric particle mixtures for
the manufacturing of tablets, and hydrocolloids serve as stabilizers in
oil-in-water emulsions (Aulton and Taylor, 2018).
This review article provides an overview of recent advances in the
use of polymers and lipids in pharmaceutical technology. It stems from
the scientiﬁc presentations given at the Annual Scientiﬁc Meeting of the
Gattefossé Foundation 2018 (“Journées Galéniques of Saint-Rémy de
Provence”, France, September 5–8th, 2018) by academic and industry
experts, all of whom are coauthors of this manuscript. Given the
breadth of the topic, the review focuses on areas of long-standing in-
terest for the pharmaceutical industry and on selected emerging tech-
nologies. These include sustained release formulations, oral delivery of
poorly water-soluble drugs and peptides, drug targeting technologies,
transfection methods, and the on-demand production of customized
delivery systems by three-dimensional (3D) printing technologies.
2. Polymer-based oral formulations
The pharmaceutical applications of polymers in oral dosage forms
span from their use as binders in tablets to viscosity and ﬂow-control-
ling agents in liquids. Their wide range of physical (i.e. density, particle
size) and chemical properties (i.e. molecular weight, substitutions) is
important to overcome formulation challenges. Polymers can be em-
ployed as ﬁlm coatings to mask the unpleasant taste of a drug, to en-
hance drug stability and to modify drug release characteristics
(Table 1). Moreover, the possibility to combine diﬀerent polymeric
excipients allows the design of novel and robust dosage forms, as well
as the production of controlled release drug delivery systems. This
section focuses primarily on the application of polymers in controlled
release tablets and amorphous solid dispersions (ASDs).
2.1. Controlled release matrix systems
Diﬀerent formulation strategies can be adopted to prepare con-
trolled release solid dosage forms. Polymeric matrix tablets are the most
popular ones for oral drug administration as they are a convenient and
relatively low-cost way to modulate the release of active pharmaceu-
tical ingredients (APIs) with a wide range of solubilities and dosage
strengths. However, formulating a robust controlled release matrix re-
quires knowledge of the physicochemical properties of both the drug
and the polymer. Commonly used polymers for controlled release are
reported in Table 1. Some examples of commercialized drugs using
these polymers are felodipine, verapamil, nifedipine, and gliclazide
(PharmaCircle, August 18th, 2018).
The underlying mass transport mechanisms controlling drug release
from polymeric controlled release tablets may vary in complexity (e.g.
Borgquist et al., 2006; Caccavo et al., 2017; Chirico et al., 2007;
Kaunisto et al., 2011; Siepmann et al., 2010, 2017; Siepmann and
Siepmann, 2008, 2012). Depending on the physico-chemical properties
of the polymer (e.g., solubility in water, swelling behavior) and the
drug (e.g. solubility in the swollen polymeric system and in the sur-
rounding release medium), a variety of phenomena might be involved
(Grassi et al., 2004; Kaunisto et al., 2010). These include water pene-
tration into the system, drug dissolution, drug diﬀusion (with constant
or time- and position-dependent diﬀusion coeﬃcients), polymer swel-
ling, drug–polymer interactions (e.g. ionic, van der Waals), polymer
dissolution, polymer degradation and tablet disintegration. Im-
portantly, not all of these processes occur in all cases and even when
they occur, they may not contribute signiﬁcantly to the resulting drug
release rate. For instance, if several mass transport processes occur
sequentially and one of them is much slower than the others, it will be
rate-limiting and dominate the overall transport.
As an example of controlled release polymeric matrix tablets,
HPMC-based matrix tablets (Kaunisto et al., 2013; Siepmann and
Peppas, 2001) are described in more detail in this section. Fig. 1 il-
lustrates their possible inner structure during drug release. On the left
side, the well-stirred release medium (bulk ﬂuid) is shown. On the right
side, the inner structure of the still dry tablet core is represented. It
consists of a polymer network in which non-dissolved drug particles
(represented as black circles) are trapped. Depending on the solubility
of the drug in the dry polymer matrix, a certain amount of API (even-
tually all) might be dissolved (i.e. being in the form of individual drug
molecules) in the polymeric system (depicted as stars in Fig. 1). The
extent of such drug dissolution in the dry polymeric network can also
strongly depend on the manufacturing procedure of the tablet.
Once the tablet comes into contact with aqueous body ﬂuids, water
penetrates the system and as soon as a critical water concentration is
reached, the HPMC chains undergo a relaxation process (swelling). This
Table 1
Common polymers used in pharmaceutical technology (Jones, 2004; Maderuelo, et al., 2011).
Vinyl polymers Cellulose ethers Other polysaccharides Miscellaneous
Polymethacrylates,
poly(acrylic acids),
poly(vinyl alcohol),
poly(N-vinyl
pyrrolidone) (PVP)
Methylcellulose, ethylcellulose,
hydroxyethylcellulose, hydroxypropyl
methylcellulose (HPMC), hydroxypropylcellulose
(HPC), HPMC acetate-succinate,
carboxymethylcellulose
Chitosan,
carrageenan,
xanthan gum,
alginic acid, tragacanth,
acacia gum
Poly(lactide),
poly(lactide-co-
glycolide),poly(ε-
caprolactone)
PEG Silicone
Primary applications
Film coating, binders,
viscosity modiﬁers,
solubilizers, controlled
release
Film coating, binders, ﬁlms, controlled release,
microencapsulation, solubilizers, stabilizers,
thickeners
Immediate and controlled
release, thickeners,
peptide delivery,
microencapsulation,
permeation enhancer
Controlled release Controlled
release,
thickeners,
binders
Immediate and
controlled
release
Common dosage forms
Oral solid, parenteral,
topical
Oral solids, topical, injectables, ophthalmic,
disperse systems, wound dressings
Oral solids, injectables,
topical
Injectables, vaccines,
implants
Oral solids,
liquids, semi-
solids
Medical devices,
implants
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creates a boundary called the “swelling front” that separates the
swollen and non-swollen matrix, and that moves (often slowly) towards
the center of the tablet. Importantly, drug mobility in the swollen
matrix is generally substantially greater than in the dry part of the ta-
blet. On the other hand, signiﬁcant polymer swelling also leads to in-
creased system dimensions, which imposes longer diﬀusion pathways to
be overcome. Hence, substantial polymer matrix swelling might slow
down drug release when compared to less intensively swelling poly-
mers. Depending on the type of drug and polymer used, the “increased
drug mobility eﬀect” or the “increased diﬀusion pathway length eﬀect”
might prevail, resulting in faster or slower drug release compared to
systems based on less swellable polymers.
Once the drug molecules are dissolved (individualized) and become
suﬃciently mobile, they diﬀuse out of the tablet due to concentration
gradients. If the drug loading is higher than the drug’s solubility in the
swollen polymer matrix, dissolved and non-dissolved drug co-exist.
Importantly, since only the dissolved drug can diﬀuse, the absolute
release rate is dictated by the concentration of dissolved drug (and not
by the total drug concentration). The swollen polymeric matrix might
be saturated with the drug, and the released drug be rapidly replaced by
the dissolution of the locally remaining non-dissolved drug excess.
Hence, the limited solubility of the drug can play a major role in the
control of drug release and the resulting release rate from polymeric
matrix tablets. Although often ignored, such “limited drug solubility ef-
fects” can be of importance even in the case of freely water-soluble
drugs and highly swollen polymer matrices; the amount of water pre-
sent in the swollen hydrogel might be insuﬃcient to dissolve all of the
drug (e.g. Siepmann et al., 2017). With time, the amount of non-dis-
solved drug locally decreases. Once all the drug excess is dissolved at a
certain position, the released drug molecules are no more replaced and
the concentration of dissolved drug at this position decreases. Conse-
quently, another front can be observed: the so-called “diﬀusion front”.
This separates the swollen polymer matrix, which is free of non-dis-
solved drug, from the swollen polymer matrix, which still contains non-
dissolved drug excess (Fig. 1). Furthermore, since HPMC is water-so-
luble, the macromolecules start to disentangle from the polymeric
network above a critical water threshold concentration (Ju et al.,
1995). This occurs at the “matrix – release medium interface”, which is
also called the “erosion front”.
The importance of the above described mass transport phenomena
occurring in HPMC matrix tablets depends on the type of HPMC (e.g.
polymer molecular weight and degree of substitution), nature of the
drug (e.g. with a speciﬁc solubility and mobility in the polymeric ma-
trix) and composition of the system (e.g. drug and polymer contents as
well as potential presence of other compounds) (e.g. Viridén et al.,
2011a,b). In addition, the conditions in the surrounding bulk ﬂuid can
aﬀect the importance of the involved mass transport phenomena and
resulting drug release kinetics (e.g. Williams et al., 2009). Generally,
the drug release rate from hydrophilic matrix tablets is determined by
several parameters such as the composition of the formulation, the
manufacturing process, and the properties of the drug itself and of the
polymers in the matrix. Indeed, molecular weight, hydrophilicity, de-
gree of cross linking and degree of substitution are all polymer para-
meters known to inﬂuence the swelling and erosion of the matrices.
One of the major potential challenges encountered during for-
mulation development involves minimizing undesired burst eﬀects and
achieving constant drug release rates (zero order kinetics, if these are
targeted), since generally release rates are initially higher and mono-
tonically decrease with time. Often, curve-shaped release proﬁles are
obtained, not linear proﬁles. Moreover, providing robust drug release
kinetics in the human body constitutes another signiﬁcant challenge.
For example, the mechanical stress experienced in the gastrointestinal
tract might accelerate the destruction of the swollen polymer matrix,
which may in turn lead to variable drug release rates in the patient.
2.2. Amorphous solid dispersions
ASDs have become key enabling tools for formulating poorly water-
soluble drug molecules (Baghel et al., 2016; Huang and Dai, 2014;
Paudel, et al., 2013). As such, they are of great value as it has been
estimated that 70% of new drug molecules under development are in-
soluble yet highly permeable drug compounds (Biopharmaceutical
Classiﬁcation System (BCS)-II), and another 20% are insoluble and
poorly permeable (BCS-IV) (Benet et al., 2011; Thayer, 2010). In
pharmaceutical sciences, the term ASD is generally used to describe a
glassy solid solution of an amorphous homogeneous miscible blend
composed of a drug compound and a polymer excipient (Fig. 2)
(Breitenbach and Magerlein, 2003; Chiou and Riegelman, 1970). In
ASDs, the disordered amorphous phase is kinetically more soluble,
providing suﬃcient driving force to enhance plasma concentrations as
long as drug crystallization can be prevented in vivo (Hancock and
Parks, 2000). This higher solubility and higher dissolution rate may
Fig. 1. Schematic representation of a HPMC controlled release matrix tablet during drug release. The stars and black circles represent dissolved and dispersed drug,
respectively. The following (moving) boundaries can be distinguished: (i) an “erosion front”, separating the bulk ﬂuid from the matrix tablet; (ii) a “diﬀusion front”,
separating the swollen polymer matrix containing dissolved drug only and the swollen polymer matrix containing dissolved and dispersed drug; and (iii) a “swelling
front”, separating the swollen and non-swollen polymer matrix. Details are described in the text. Adapted from Siepmann and Siepmann, 2008, with permission from
Elsevier.
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enhance bioavailability, as a drug must be in solution to be orally ab-
sorbed in the gastrointestinal tract and reach systemic circulation. The
solubility enhancement may be low, one to two-fold, or more sig-
niﬁcant such as the 10-fold achieved with amorphous novobiocin. It
may also reach as much as 1600-fold or higher (Hancock and Parks,
2000); although, most supersaturations achieve concentrations between
10 and 60-fold the crystalline solubility (Almeida e Sousa et al., 2015).
While it is possible to develop a dosage form using an amorphous
drug substance, addition of anti-nucleating polymers is often required
to stabilize the drug compound in the amorphous phase. Nabilone
(Cesamet®) and verapamil (Isoptin-SR-E®) are examples of early-mar-
keted ASDs, consisting of the API melt-extruded in PVP and HPC/
HPMC, respectively (Huang and Dai, 2014; Ting et al., 2018).
ASDs are prepared using several techniques including grinding,
solvent evaporation (e.g. lyophilization, spray-drying, spray-freezing,
spray-congealing), fusion (e.g. hot-melt extrusion, HME), co-precipita-
tion (e.g. supercritical ﬂuid precipitation) (Chauhan et al., 2005) and
more recently 3D printing (Kyobula et al., 2017). The types of stabi-
lizing polymers used have expanded from the cellulosic polymers and
synthetic polymers, such as HPMC and PVP, to novel ones designed
speciﬁcally to stabilize the ASD (Arca et al., 2018; Ting et al., 2018).
Arca et al. (2018) synthesized ω-carboxyalkanoate-modiﬁed cellulose
polymers to stabilize rifampin, which prevented the acid-catalyzed
degradation occurring under gastric conditions, ensuring complete re-
lease of the API and increasing bioavailability. Moreover, combinations
of polymers, binary and ternary systems, have been explored to further
optimize polymer dispersions. In these cases, the main challenge lies in
maintaining miscibility of all the components without leading to crys-
tallization of the drug compound and changes in the release proﬁles of
the ASD. The additional components may also include surfactants and
lipids which are added to enhance dissolution rates and solubilization in
vivo (vitamin E TPGS, Gelucire® 44/14, polysorbate 80, Kolliphor® EL
and HS15). The inclusion of these solubilizers has demonstrated im-
proved drug release and enhanced bioavailability (Bley et al., 2010).
However, the addition of dissolution enhancers can also create the risk
of phase separation, immiscibility in the polymer blends, and pre-
cipitation of the crystalline drug molecule either in the matrix or upon
dissolution; and may also reduce in vivo release of the API reducing
absorption (Chen et al., 2016; Deshpande et al., 2018; Harmon et al.,
2016). Other modiﬁcations involve the incorporation of cyclodextrin
inclusion complexes or spraying onto a substrate such as mannitol. A
high surface area material such as magnesium aluminometasilicate or
silicon dioxide may be added to enhance stability and bioavailability
(Alhijjaj et al., 2017; Bley et al., 2010). Despite the numerous pub-
lications on ASDs, the number of polymers used in products remains
limited to a few (HPMC, HPC, HPMC acetate succinate, PVP, PVP-vinyl
acetate, PEG, poloxamer), reﬂecting the complexity behind regulatory
approvals of novel polymers and their adoption by the pharmaceutical
industry (Huang and Dai, 2014).
The melting temperature can be considered the most important
parameter of the crystalline state, however in the case of ASDs the glass
transition temperature, an indicator of the onset of molecular mobility,
deﬁnes the signiﬁcant properties of the amorphous state (Eisenberg,
1993). A miscible homogeneous solid dispersion with a single glass
transition temperature is preferred over an immiscible dispersion with
multiple glass transition temperatures because of its enhanced stability
due to the favorable drug-polymer interactions and reduced molecular
mobility (antiplasticization). Non-homogeneous or phase-separated
dispersions, consisting of drug-rich amorphous domains in the amor-
phous polymer (two glass transition temperatures) as well as polymer
dispersions containing crystalline drug (Fig. 2), do not provide the
desired stability or solubility enhancement. The strength of the non-
covalent drug-polymer interactions (H-bonding, van der Waals, ionic
interactions, electrostatic, hydrophobic, ion-dipole) (Baghel et al.,
2016) is critical as these inhibit the potential for crystallization; how-
ever, they may also reduce the liberation of the drug molecule from the
polymer matrix. Generally, higher molecular weight polymers with
reduced hygroscopicity are preferred (Huang and Dai, 2014). However,
plasticization by water as the polymer dissolves, can increase mobility
and migration of drug molecules, and may subsequently result in
crystallization. The success of a drug-polymer amorphous dispersion is
often described in terms of a spring and parachute (Fig. 3). As the ﬂuid
penetrates the solid amorphous dispersion, the polymer dissolves along
with the amorphous drug molecules to create a supersaturated solution
with respect to the solubility of the crystalline solid (spring). The pro-
longed duration of this supersaturation is described as the parachute and
contributes to the success of the ASD in enhancing the absorption of the
drug molecule in vivo. However, the challenge is to maintain the su-
persaturation. Bergstrom and coworkers (Edueng et al., 2017) showed
that modifying surface properties was important; indeed, even low
amounts of polymer (0.001 to 0.01% of HPMC) could reduce the
crystallization at the water interface. However, in practice, the
Fig. 2. Possible structures for drug-polymer disper-
sions. Left: drug is molecularly dispersed (amor-
phous) in the polymer matrix; a preferred stabilized
ASD (single glass transition temperature). Middle:
phase separated with amorphous drug-rich and
amorphous polymer-rich phase (likely two glass
transition temperatures). Right: phase separated
with a crystalline drug-rich phase and an amorphous
polymer-rich phase (Huang and Dai, 2014; Meere,
et al., 2017).
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preferred drug loads in ASDs vary from 20% to 50% depending on the
crystallization risk of the drug compound, whether it is a fast or slow
crystallizer (Friesen et al., 2008).
Various modeling attempts to aid in the rational selection of the
ASD polymer excipients have included Hildebrand Solubility
Parameters, δ, Flory-Huggins χ-interaction parameter, and diﬀerent
molecular descriptors such as mobility, enthalpic driving force, hy-
drogen bonding, entropic barrier to crystallization, molecular weight,
number of rotating bonds, etc. (DeBoyace and Wildfong, 2018). A re-
cent molecular modeling study by Fridgeirsdottir et al. (2018) evalu-
ating the results of 60 solid dispersions with 10 molecularly diﬀerent
drug molecules (see Section 5), three diﬀerent polymers and two
manufacturing processing methods (spray-drying and HME), suggested
that the key important parameters for achieving higher ASD stability
were: (1) increased glass transition of the ASDs relative to that of the
drug molecule; (2) increased molecular ﬂexibility of the drug molecule
(lower propensity to crystallize); and (3) decreased number of drug
molecule donor H-bonds. The latter parameter was attributed to the
enhanced drug-drug molecular interactions or drug-water molecular
interactions resulting from APIs with increased H-bond donors com-
pared to those with lower H-bond donor capabilities. These molecules
did not form enhanced drug-polymer interactions, thus reducing sta-
bility (Fridgeirsdottir et al., 2018). Future research should focus on
better understanding the selection of polymer combinations, with or
without additives such as surfactants and lipids, to further enhance
bioavailability and facilitate the development of standard prototype
formulations based on the physicochemical properties of the drug
molecules. The challenges with ASDs are several and include the se-
lection of polymers and combinations, and the accommodation of high
API doses into a single dosage form. In addition to the above, it is
important to ensure chemical and physical stability in the solid state
over the shelf-life of the drug product, and to maintain suﬃcient su-
persaturation of the drug in vivo to provide higher bioavailability. De-
spite the signiﬁcant interest and the number of publications on amor-
phous solid dispersions, there have been less than 35 FDA-approved
ASDs to date (Huang and Dai, 2014, Huang and Williams, 2018). Yet,
ASDs have become an important part of a formulator’s armamentarium,
enabling non-clinical safety and toxicity studies as well as bringing
insoluble, poorly orally bioavailable drug compounds to the market
particularly in cases where molecular design does not permit ameli-
oration of the properties of potent drug compounds.
3. Lipid-based oral formulations
Lipids play an essential role in the oral delivery of a wide variety of
APIs. They are highly versatile in terms of structure – a fact often
recognized with polymers, but rarely highlighted for lipids. Lipids are
natural dietary components and besides serving as sources of energy,
they are suitable carriers for the delivery of poorly water-soluble vita-
mins and nutrients to the body through favorable interactions with
endogenous bile components. Lipid structures are digested by lipases to
form smaller absorbable components (monoglycerides and fatty acids).
These provide the speciﬁc and non-speciﬁc interactions with lipophilic
drugs that enable their solubilization and absorption (Porter et al.,
2007). This section of the article focuses on the dynamic self-assembly
structures that lipids adopt in aqueous environments following ad-
ministration, and on their impact on drug delivery.
Lipid-based excipients are ingredients derived from vegetable oils,
fatty acids or waxes. Vegetable oils comprise triacylglycerols (fatty acid
esters of glycerol), phospholipids and lipophilic vitamins (Jannin et al.,
2008). They are used to produce a wide variety of ingredients by var-
ious processes such as hydrogenation, esteriﬁcation (of the fatty acids),
transesteriﬁcation, and ethoxylation. The latter three processes use al-
cohols to produce more hydrophilic ingredients. Alcohols can be either
small molecules such as glycerol or propylene glycol, or polymers like
PEG or polyglycerols. The physical properties of these lipid-based in-
gredients are mainly inﬂuenced by the unsaturation in fatty acids, the
fatty acid chain length and potential ramiﬁcation, the type of alcohol
selected and the number of ester/ether functions (polarity). Hence,
these ingredients can be either liquid or solid, exhibiting various
polymorphic phases (Brubach et al., 2004), polar but insoluble (swel-
ling – forming liquid crystalline phases - or not in contact with aqueous
environment) or water-soluble (forming micelles) (Small, 1968). The
critical material attributes of lipid-based excipients are linked to the
origin and quality of the fatty acids and alcohols as well as process
conditions to minimize the creation of impurities potentially aﬀecting
the functionality of those excipients (Jannin et al., 2014).
3.1. Oily solutions and self-emulsifying drug delivery system
The functionality of lipid systems with respect to transport and oral
delivery of poorly water-soluble APIs is critically linked to their pro-
pensity to self-assemble in aqueous environments (Fig. 4). The struc-
tures formed depend on the speciﬁc lipids present, and the way in
which the molecules can geometrically pack together in the self-as-
sembled structure. The geometry of packing of the lipids can be pre-
dicted using the concept known as the ‘critical packing parameter’
which relates the eﬀective molecular dimensions (headgroup size, tail
length and volume) to the likely structures formed (Israelachvili et al.,
1976), and can be probed using conventional colloidal characterization
approaches. The structure of the particles formed also dictates their
surface characteristics and consequent interaction with bio-interfaces
such as mucus. Drugs have diﬀerential aﬃnities for these structures
(Kossena et al., 2003), and understanding the formation and sig-
niﬁcance of the latter has been a holy grail in the ﬁeld. Importantly, it is
the pre-absorptive environment and not necessarily the formulation
itself that ultimately dictates drug absorption. In the case of poorly
water-soluble, weakly basic drugs, digestion of ester-containing lipids is
key for drug solubilization prior to absorption from the small intestine.
Characterizing this highly dynamic and complex system is key to un-
derstanding the determinants of lipid self-assembly, drug solubilization
and absorption, and constitutes an evolving ﬁeld that is currently being
addressed using advanced time-resolved techniques (Warren et al.,
2011).
Lipid-based excipients are currently used in various oral dosage
forms, such as oily solutions and self-emulsifying drug delivery systems
(SEDDS), to increase the bioavailability of poorly soluble drugs
(Table 2). The enhancement in bioavailability by oily solutions and
SEDDS is, for poorly water-soluble lipophilic drugs, mainly due to the
pre-dissolution of the drug in the formulation, which spares the need for
this step in the gastrointestinal tract. The performance of such systems
is dependent on their ability to form colloidal phases intraluminally
Fig. 3. Dissolution to form a supersaturated solution followed by rapid crys-
tallization (spring) or prolonged supersaturation (spring+ parachute) of a drug
compound with an equilibrium solubility, Ceq. (Brough and Williams, 2013;
Meere, et al., 2017). Reproduced from Brough and Williams (2013) with per-
mission from Elsevier.
J. Siepmann et al. International Journal of Pharmaceutics 558 (2019) 128–142
132
that maintain the drug in a solubilized state. These systems also in-
crease the kinetics of drug absorption by creating a local super-
saturation close to the intestinal epithelium through the absorption of
lipid metabolites (Yeap et al., 2013). The translation of this technique
into commercial drug products is important as over 150 oral products
are currently marketed with the technology referred as ‘lipid & SEDDS’
in PharmaCircle. Most of these formulations are composed of liquid
lipid excipients that are encapsulated in either soft or hard gelatin
capsules.
In the last decade, the interest in ‘solid SEDDS’ has risen and cur-
rently various solidiﬁcation techniques or processing technologies of
semi-solid or solid excipients are being investigated. Among these, the
HME process (Vithani et al., 2017) and 3D printing (see Section 5)
(Jannin et al., 2017) allow solid SEDDS to be obtained directly without
a solid phase carrier, while maintaining their self-emulsifying and so-
lubilizing properties. The same approach is now being used to enhance
the oral bioavailability of therapeutic peptides (Section 3.2) (Menzel
et al., 2018) and nucleic acid-based therapeutics (Hauptstein et al.,
2015), given their ability to limit the metabolic degradation of these
molecules and increase the intestinal absorption. Upon contact with
body ﬂuids such as the intestinal ﬂuid, SEDDS spontaneously form oily
droplets in the range of 50–500 nm. Drugs (e.g. peptides and nucleic
acids) exhibiting a log D SEDDS/release medium < 2 are immediately re-
leased from these oily droplets (Bernkop-Schnürch and Jalil, 2018).
Therefore, a sustained release can likely only be achieved by the for-
mation of hydrophobic ion pairs with a preferred log D > 3 (Griesser
et al., 2017b). In case of a low log D, the release from the oily droplets is
mainly dictated by the drug absorption process from the gastro-
intestinal mucosa. Alternatively, in case of a log D > 3, the drug re-
lease can be controlled by the degradation of the oily droplets in the
intestine by lipases. Furthermore, a controlled drug release can be
achieved by the incorporation of amphiphilic polymers in SEDDS
keeping the drug for a prolonged time period in the oily droplets due to
ionic interactions such as between a hydrophobized polycation and an
anionic drug.
Even with adequate dissolution, the bioavailability of many drugs is
limited by eﬄux mechanisms that non-speciﬁcally shuttle xenobiotics
back out of the absorptive enterocytes. Lipids (and some amphiphilic
polymers) can interact with the proteins that facilitate these processes
as a decoy to enable the drug to passage further into the enterocytes and
avoid this obstacle to bioavailability (Li et al., 2013; Werle, 2008). Most
absorbed molecules, including drugs, will then exit the cellular en-
vironment through the dominant passage into the portal blood supply,
due to the high blood ﬂow acting as an eﬀective sink. However, highly
lipophilic drugs with a deﬁned set of physicochemical properties, and in
the presence of certain lipids, may also take the less dominant route of
entering the bloodstream via the lymphatic system (Porter et al., 2007).
3.2. SEDDS for the delivery of poorly permeable drugs
SEDDS have the potential to facilitate the delivery of poorly
permeable drugs. Emerging data shows that their combination with
polymers could improve the oral absorption of therapeutic peptides
(Mahmood and Bernkop-Schnürch, 2018). Polymeric excipients can
grant SEDDS diverse properties, such as drug release control, mucus
permeation or mucoadhesion, zeta potential modulation and cell pe-
netration.
The ability to permeate the mucus gel layer and reach the under-
lying epithelial membrane is essential for certain drug delivery systems.
In comparison to other types of nanocarriers such as nanoparticles and
liposomes, SEDDS exhibit greater mucus-permeating properties
(Griesser et al., 2018). In particular PEGylated surfactants like Kolli-
phor® and polysorbates seem to provide a slippery surface for SEDDS as
their hydrophilic PEG substructures exhibiting muco-inert properties
Fig. 4. Lipid formulations, often ﬁlled into a soft gelatin capsule, undergo dispersion and digestion of the lipids by lipases in the gut, followed by self-assembly of the
lipid digestion products into colloidal structures. The fate of the co-administered drug (D) is dictated by its interaction with those structures prior to absorption (as
illustrated in last panel on the right).
Table 2
Examples of oily solutions and SEDDS in marketed drug products (extracted from a PharmaCircle search with the technology keyword ‘lipid & SEDDS’ performed on
August 23rd, 2018).
Type of formulation Composition (excluding antioxidants) API (Marketed drug products, manufacturer)
Oily solution Medium chain triglycerides Calcitriol (Rocaltrol, Roche Laboratories)
Oily solution Medium chain triglycerides, lecithin, caprylic/capric mono/diglycerides, PEG Dutasteride (Avodart, GlaxoSmithKline)
SEDDS Linoleyl polyoxyl-6 glycerides Ethinylestradiol / norethindrone acetate (Taytulla, Allergan)
SEDDS Ethanol, linoleyl polyoxyl-6 glycerides, corn oil Cyclosporine A (Sandimmune, Novartis)
SEDDS Ethanol, propylene glycol, corn oil, polyoxyl-40 hydrogenated castor oil (Cremophor*
RH40)
Cyclosporine A (Neoral, Novartis)
SEDDS Caprylocaproyl polyoxyl-8 glycerides (Labrasol ALF) Enzalutamide (Xtandi, Astellas)
SEDDS Lauroyl polyoxyl-32 glycerides (Gelucire 44/14), PEG, HPC, sodium starch glycolate Fenoﬁbrate (Lipofen, Kowa Pharm.)
SEDDS Polyoxyl-35 castor oil (Cremophor* EL), oleic acid, Ethanol Ritonavir (Norvir, Abbott) - discontinued
SEDDS Stearoyl polyoxyl-32 glycerides (Gelucire 50/13), sorbitan monooleate, soybean oil Isotretinoin (Absorica, Sun Pharma)
* Cremophor® has been rebranded as Kolliphor®.
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assemble on the surface of the oily droplets. Menzel et al. (2018), for
instance, reported highly mucus-permeating SEDDS for the adminis-
tration of exenatide, achieving an oral bioavailability of 14.6% vs.
subcutaneous injection (Fig. 5) (Menzel et al., 2018). As an alternative
to PEG-coating, SEDDS can be coated with mucolytic enzymes such as
papain. Via hydrophobic ion-pairing with oppositely-charged ionic
surfactants (e.g. deoxycholate), the proteolytic enzyme can be anchored
on the surface of the oily droplets from where it will cleave mucus
glycoproteins as the droplets make their way to the epithelium (Menzel
and Bernkop-Schnürch, 2018).
In addition to mucus-permeating capabilities, mucoadhesive prop-
erties can improve SEDDS’ eﬃcacy. Increasing their residence time on
mucosal membranes extends the time that is available for drug ab-
sorption, which may in turn lead to a prolonged therapeutic eﬀect. By
incorporating hydrophobized mucoadhesive polymers into SEDDS,
their bioadhesion can be dramatically increased. Chitosan-fatty acid
conjugates may be used for this purpose (Eﬁana et al., 2017), as well as
hydrophobic thiolated polymers capable of forming covalent bonds
with cysteine-rich mucus substructures, such as thiolated Eudragit®
S100 (Leonaviciute et al., 2017). Sakloetsakun et al. (2013), for in-
stance, showed a signiﬁcantly increased systemic insulin exposure in
rats after oral administration of insulin-loaded SEDDS containing a
thiolated polymer (Sakloetsakun et al., 2013).
As mucus carries a net negative charge because of sialic and sulfonic
acid residues, oily droplets exhibiting a positive zeta potential get re-
tained in the mucus due to ionic interactions. In contrast, uncharged or
negatively charged oily droplets exhibit comparatively higher mucus-
permeating properties. In close proximity to the cell membrane, how-
ever, the situation changes completely as now adhesion rather than
repulsion is the aim. Similar to the mucus, intestinal epithelial cells
exhibit a negative surface charge due to the presence of high-density
negatively charged molecular species (including polar carbohydrates
and charged amino acid side chains), which repel negatively charged
nanocarrier systems from the membrane (Bennett et al., 2014). To
overcome this repulsion, a positive zeta potential seems to be ad-
vantageous. For this purpose, SEDDS that change their zeta potential
from a negative charge throughout the mucus gel layer towards a po-
sitive zeta potential on the absorption membrane have been developed.
Zeta potential-shifting SEDDS have been designed by combining a
cationic surfactant and a phospholipid (1,2-dipalmitoyl-sn-glycero-3-
phosphatidic acid) in the SEDDS pre-concentrate. Due to the enzymatic
cleavage of the phosphate ester on the phospholipid by intestinal al-
kaline phosphatase, the oily droplets were shown to change their zeta
potential in the demanded manner (Suchaoin et al., 2016). The shift in
zeta potential was even more pronounced when phosphorylated hy-
droxypropyl starch was incorporated in the SEDDS (Griesser et al.,
2017a). Unfortunately, the inclusion of polymers in SEDDS is in many
cases limited by their poor solubility in the lipophilic phase. Because of
this limitation, certain polymers cannot be incorporated at all or only to
a minor extent, meaning that the desired eﬀect cannot be achieved.
Another strategy intended to improve attachment and uptake by
mucosal epithelial cells involves the use of cell-penetrating peptides.
The HIV-1 Tat-protein 49–57 cell-penetrating peptide, for instance, has
been covalently attached to oleic acid, providing a lipophilic anchor in
the oily droplets formed by SEDDS. Improved cellular uptake of Tat-
decorated SEDDS was conﬁrmed through confocal microscopy, which
revealed clathrin- and caveolae-mediated endocytosis as the major
pathways for internalization (Mahmood et al., 2016).
4. Nanocarriers based on lipids and polymers
4.1. Lipidic and polymeric vesicles
Vesicles consist of an aqueous lumen enclosed by bilayer mem-
branes, which can be composed of supramolecular amphiphilic lipids or
synthetic block copolymers, forming liposomes or polymersomes, re-
spectively. The ﬁrst liposomes were reported by Bangham et al. (1965),
who demonstrated the very slow diﬀusion of ionic species through
phospholipidic bilayers with the aim of mimicking biological cell
membranes. Based on the number of bilayers, vesicles can be classiﬁed
as unilamellar or multilamellar. Unilamellar vesicles are of particular
interest in biomedical applications, and can be further classiﬁed ac-
cording to their size as small, large and giant unilamellar vesicles. Three
decades later, Zhang and Eisenberg (1995) published the ﬁrst report on
vesicle formation with amphiphilic poly(styrene)-b-poly(acrylic acid)
copolymers, which were later on named polymersomes by Discher et al.
(1999). The latter established robust relationships between amphiphilic
molar mass, bilayer thickness and membrane properties on PEG-b-
polybutadiene copolymers (Discher and Eisenberg, 2002). Since then,
polymersomes have emerged as promising bioinspired compartments
for various applications (De Oliveira et al., 2012).
Liposomes and polymersomes are extensively investigated as na-
nocarriers for loading, delivering and releasing hydrophobic or hydro-
philic drugs, biologics and diagnostic agents in a controlled manner
(Palivan et al., 2016; Torchilin, 2005; Upadhyay et al., 2009). In the
case of liposomes, given their resemblance to cellular structures, they
are also widely exploited to study the biophysical properties of biolo-
gical membranes (e.g. stability, permeability, phases, domains and
curvature), and to develop membrane-based biosensors (Osaki and
Takeuchi, 2017). Today, liposomes are part of vaccine and cosmetic
formulations, but perhaps the most popular application remains their
use as nanomedicines (Allen and Cullis, 2013). Liposomes have pro-
vided clinical beneﬁts for over 20 years since the approval of Doxil® in
1995 (Fig. 6). The latter is an injectable PEGylated liposomal for-
mulation of doxorubicin (ca. 80 nm) (Wibroe et al., 2016) with an
improved therapeutic index compared to free doxorubicin. It is cur-
rently approved for the treatment of AIDS/HIV Kaposi’s sarcoma,
multiple myeloma and ovarian cancer. The PEG coating reduces the
uptake of the liposomes by the mononuclear phagocytic system, ex-
tending the circulation time (elimination half-life of 20–30 h in human),
and in some cases increasing doxorubicin deposition in permeable tu-
moral areas that exhibit the so-called enhanced permeability and re-
tention (EPR) eﬀect (Barenholz, 2012; Maeda, 2010). There are cur-
rently ca. 15 types of liposome-based pharmaceutical products on the
market, and intensive development of liposomal formulations is
Fig. 5. Plasma concentration–time curve of exenatide in rats after oral ad-
ministration via highly mucus-permeating SEDDS (dose: 150 µg) (○) and after
subcutaneous injection of exenatide solution (dose: 20 µg) (●). Indicated values
are the means of at least three experiments ± standard deviation; adapted with
permission from Elsevier (Menzel, et al., 2018).
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ongoing worldwide with 28 products under clinical evaluation (Bulbake
et al., 2017).
Although liposomes possess advantageous attributes in terms of
safety and biodegradability, the fragile nature of their lipid bilayer and
diﬃculties in formulation and functionalization of lipids may restrict
their development in certain cases (e.g. delivery to the gastrointestinal
tract) (Le Meins et al., 2013; Wibroe et al., 2016; Yingchoncharoen
et al., 2016). The emergence of polymersomes, which are characterized
by chemical versatility, high stability and toughness, has brought new
delivery opportunities (Discher and Ahmed, 2006; Le Meins et al.,
2011; Lee and Feijen, 2012). Owing to their unique properties, poly-
meric vesicles may oﬀer some advantages over liposomes: i) a broad
range of diﬀusion properties can be easily achieved by chemistry
(Discher and Eisenberg, 2002); ii) very long circulation times can po-
tentially be attained due to the high density of PEG chains; iii) high
loading eﬃciency of hydrophobic drugs can be obtained within the
thicker membrane (up to 10-fold increase compared to lipid bilayers),
additionally allowing for multiple drug loadings (Ahmed et al., 2006);
iv) accurate engineering of a responsive building block that allows
speciﬁc and controlled release properties can be done. Nevertheless,
polymersomes have not yet made it into the market, which probably
reﬂects the inherent diﬃculty to approve any novel excipient. Another
possible factor slowing down polymersome translation into the clinic
may be the technical diﬃculty in scaling-up the manufacturing of
monodisperse nano-sized polymersomes, even if emerging technologies
such as microﬂuidics constitute promising fabrication alternatives
(Upadhyay et al., 2009).
Polymersome and liposome formulations are expected to further
evolve and ﬁnd their utility in newer indications (e.g. cancer im-
munotherapy, inﬂammatory diseases, etc.) (Alaarg et al., 2017; Dianat-
Moghadam et al., 2018). In particular, the possibility to incorporate
both diagnostics agents and drugs as well as to control the release rate
and endow these vesicles with targeting moieties makes them particu-
larly attractive for the development of personalized therapies. The op-
tion to combine both lipids and polymers in the membrane structure
further adds to the versatility of these systems. Interestingly, hybrid
bilayer vesicles (polymer/polymer or polymer/lipid) (Le Meins et al.,
2013) have attracted particular attention in which the polymer sup-
ports mechanical stability, whereas the lipid provides domains with
speciﬁc interactions or permeability. Flexible assembly of these am-
phiphiles in bilayers where lipid/polymer deposits at inner-leaﬂet or
outer-monolayer creates a new class of vesicle-based systems aiming to
improve the delivery eﬃcacy (Peyret et al., 2018a,b).
In conclusion, the main arguments in favor of liposomes are that
they have a long history with decades of research to understand their
structure/properties relationships, they are generally bio-based, bio-
compatible, metabolizable and very well tolerated. The main drawback
of liposomes originates from their general instability, especially during
certain functionalization steps. Polymersomes oﬀer the general scaling
laws of polymer and the speciﬁcity of the chemistry, allowing accurate
design of structures with controlled and predictable properties, in terms
of diﬀusion, stability and degradability.
4.2. Polymer-based nanoparticles and micelles
While liposomal formulations of anti-cancer drugs still dominate the
oncology nanomedicine ﬁeld (Barenholz, 2012), several polymer-based
nanosystems are either currently approved for use or in clinical de-
velopment for various types of cancers (Fig. 6) (Houdaihed et al.,
2017). Due to the unparalleled diversity associated with the design and
synthesis of polymers, their integration into a nanotechnology platform
oﬀers many exciting possibilities. The polymeric nanosystems that are
most advanced in terms of pharmaceutical development include na-
noparticles and spherical block copolymer micelles (BCMs), albeit other
types such as dendrimers are also under investigation (Prabhu et al.,
2015). Polymeric nanoparticles are solid colloidal systems on which a
drug is adsorbed, entrapped or chemically conjugated. BCMs are gen-
erally composed of di- or tri- block amphiphilic polymers that self-as-
semble in aqueous media to entrap (either physically or chemically) a
hydrophobic drug within its hydrophobic core. With respect to success
in the clinic, this has mainly been conﬁned to micelle-based systems
thus far.
In 1974, the ﬁrst controlled release polymer system for macro-
molecules and other drugs (in this case hormones) was reported (Davis,
Fig. 6. Timeline of polymeric and liposome-based nanoparticles’ discovery, clinical development, failures and approvals. From 1960 to the mid-1990′s, there was a
surge in the development of nanoparticle delivery systems including polymeric micelles, liposomes, dendrimers, poly(lactide-co-glycolide) (PLGA)-PEG and poly
(alkylcyanoacrylate) nanoparticles (Bangham, et al., 1965; Blume and Cevc, 1990; Buhleier, et al., 1978; Elworthy, 1960; Gref, et al., 1994; Klibanov, et al., 1990;
Langer and Folkman, 1976; Vauthier, et al., 2003; Yokoyama, et al., 1987). Several successes since that time have included Doxil®, Depotcyt®, Myocet®, Genexol®PM
and patisiran (Pillai, 2014) (Adams, et al., 2018). Despite these, several high-proﬁle failures have been reported in recent years including BIND-014 (Ledford, 2016)
and Livatag® (Reig, et al., 2017).
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1974). Over 30 years later, the ﬁrst polymer-based nanosystem was
approved for use in humans. In 2007, Genexol®-PM (a paclitaxel micelle
formulation) received approval in South Korea for the treatment of
patients with metastatic breast cancer, non-small cell lung cancer and
ovarian cancer (Van Gaal and Crommelin, 2015). Genexol®-PM is an
example of a spherical polymeric micelle system that eﬀectively solu-
bilizes its hydrophobic cargo. Using block copolymers to formulate the
drug spares the need for potentially harmful surfactants, such as Kol-
liphor® EL (in Taxol®)) and polysorbate 80 (in Taxotere®), which have
been shown to cause hypersensitivity reactions and other forms of
toxicity (Baur et al., 2008; Gelderblom et al., 2001; Szebeni et al.,
1998).
A major advantage of polymeric nanosystems is the improvement in
the toxicity proﬁle of their chemotherapeutic cargo. NC-6004
(Nanocarrier Co.) is a PEG-b-poly(glutamic acid) BCM formulation of
cisplatin currently being evaluated in Phase III clinical trials for the
treatment of head and neck as well as pancreatic cancer. In a Phase I
clinical trial, NC-6004 demonstrated less severe and less frequent
toxicities including nephrotoxicity, neurotoxicity and ototoxicity when
compared to free cisplatin (Plummer et al., 2011). Improved toxicity
proﬁles relative to the free drug were also observed with other for-
mulations, including NC-4016 (Nanocarrier Co.), NK105 (Nanocarrier
Co.), Cynviloq™ (Nantworks™), Nanoxel™-PM (Samyang Biopharm) and
CriPec® (Cristal Therapeutics) (Houdaihed et al., 2017).
Another beneﬁt to using polymeric nanosystems is the extension of
the circulation half-life of the encapsulated drugs, which allows for the
exploitation of the EPR eﬀect to increase their deposition at the tumor
site (Matsumura and Maeda, 1986). Several polymer-based nano-
particles have shown in clinical trials an inherent ability to exploit this
phenomenon. In a Phase I clinical trial, NanoCarrier’s NC-6004 de-
monstrated a 230-fold increase in the plasma half-life relative to free
cisplatin (Plummer et al., 2011). In addition, the administration of
paclitaxel formulated in NanoCarrier’s NK105 (BCM of PEG and poly
(aspartic acid) esteriﬁed with 4-phenyl-1-butanol) in a Phase I clinical
trial resulted in an increased area under the curve for plasma con-
centration vs. time and tumor exposure relative to paclitaxel as Taxol®
(Hamaguchi et al., 2007). The improvement of the pharmacokinetic
proﬁles of these drugs in polymeric nanoparticle systems increases the
likelihood that they will accumulate at the tumor site at a ther-
apeutically relevant dose.
Besides acting as carriers, polymeric nanosystems are amenable to
the co-delivery of combinations of drugs at speciﬁc molar ratios.
Triolimus (Co-D Therapeutics) is a PEG-b-poly(D,L lactide) (PEG-b-PLA)
micelle system encapsulating three hydrophobic drugs at a synergistic
ratio: paclitaxel, rapamycin and 17-N-allylamino-17-demethox-
ygeldanamycin. This nanosystem has demonstrated superior eﬃcacy
relative to free drugs and mono- and di- encapsulated systems in several
preclinical models of cancer (Hasenstein et al., 2012; Shin et al., 2011;
Tomoda et al., 2017).
A major barrier to overcome with regards to polymeric micelle
systems is thermodynamic instability when diluted following in-
travenous administration to concentrations below the critical micelle
concentration of the polymer (Fahr and Liu, 2007). For less stable mi-
celle systems, this dilution results in the dissociation of the micelle
structure and premature release of the drug before the tumor site is
reached. This inherent instability is often the major limitation of
polymeric micelle systems over their lipidic counterparts. Therefore, it
is critical to design BCM systems with adequate thermodynamic and/or
kinetic stability.
The ﬁeld of polymer-based nanomedicine was negatively impacted
in May 2016 when BIND therapeutics (a nanotechnology company
based in Cambridge, Massachusetts) went bankrupt as a result of a
failed high-proﬁle clinical trial (Weisman, 2016). The company’s lead
compound BIND-014 was a PEG-b-PLA nanoparticle formulation en-
capsulating docetaxel and targeting the PSMA, which is overexpressed
in prostate cancer as well as on the neovasculature of several non-
prostatic solid tumors (Chang et al., 1999; Rajasekaran et al., 2005).
BIND-014 was the ﬁrst targeted controlled release polymeric nano-
particle to enter clinical trials (Von Hoﬀ et al., 2016). A successful
Phase II clinical trial in 64 patients with non-small cell lung cancer
(NCT01792479) spurred its development. However, a disappointing
Phase II clinical trial (NCT02479178) in head and neck cancer, halted
its progression in the clinic. Pﬁzer picked up BIND’s assets in 2016 but
the fate of this technology remains unclear (Boyle, 2016). Despite this
setback, the versatility as a platform technology combined with several
promising clinical trials to date suggests a bright future for polymeric
based drug delivery in oncology and other indications.
4.3. Nucleic acids – The pulmonary route example
Since the beginnings of nucleic acid delivery using DNA antisense
oligonucleotides (AON) to modulate target gene expression in the
1970 s, the vision of exploiting nucleic acids as a form of therapeutics
rather than just an in vitro tool has grown substantially (Séguin and
Ferrari, 2009). In 2006, Fire and Mello were awarded the Nobel Prize in
physiology for discovering gene silencing by long double-stranded RNA
(dsRNA) (Fire et al., 1998) in a process called RNA interference (RNAi).
By the time the prize was attributed, RNAi had already advanced well
beyond its early application in functional genomics and had entered
drug development (Dorsett and Tuschl, 2004; Gomase and Tagore,
2008). Many hoped that by inducing transient and reversible gene
knockdown with short interfering RNA (siRNA), a drug-like approach
for the treatment of so far “undruggable” diseases might have been
found (Verdine and Walensky, 2007). Unfortunately, shortly after many
of the leading pharmaceutical companies shut down their eﬀorts and
research groups focusing on siRNA delivery (Ledford, 2010), the main
reason being delivery diﬃculties. While several of the initial clinical
trials on therapeutic siRNA used “naked”, unformulated siRNA for di-
rect administration in the eye (Shen et al., 2005; Tolentino et al., 2004)
or for nasal and pulmonary delivery (DeVincenzo et al., 2008; Ozcan
et al., 2015), it was soon acknowledged that for most administration
routes, a delivery system was necessary. However, formulations opti-
mized for DNA delivery did not hold the promise for siRNA (Merkel
et al., 2011), and the characteristics of short double-stranded RNA had
to be taken into consideration for developing siRNA-speciﬁc delivery
systems.
Stable nucleic acid lipid particles (SNALP) were amongst the ﬁrst
nano-enabled formulations that entered clinical settings. Alnylam in
collaboration with Tekmira targeted what could be considered the low-
hanging fruit, exploiting liver accumulation of the nanoparticles for
gene silencing in the liver (Zimmermann et al., 2006), an approach that
resulted in the approval of patisiran in 2018 (Fig. 6). However, siRNA
was expected to address more than liver diseases. Due to the ineﬃcient
targeting of siRNA to organs other than the liver, rapid degradation by
nucleases, and fast excretion upon systemic injection (Dykxhoorn et al.,
2006), other administration routes were explored in academia and in-
dustry. As an example of local administration, pulmonary siRNA de-
livery has been extensively tested in preclinical settings using animal
models of viral infection, acute lung injury, asthma, cystic ﬁbrosis,
tuberculosis, and lung cancer (Merkel et al., 2014; Ruigrok et al., 2016).
Since a variety of lethal lung disorders are among the top ten causes of
death worldwide, it is clear that pulmonary medical needs remain
unmet despite the fact that the lung is directly accessible by inhalation
(WHO, 2011). Aerosol delivery has numerous advantages over systemic
administration such as local targeting, immediate availability, de-
creased systemic side eﬀects and non-invasive application. Hence,
several obstacles encountered in systemic drug delivery can be over-
come by pulmonary delivery (Durcan et al., 2008). Pulmonary for-
mulations also feature a history of patient acceptability and compliance
because localized aerosol delivery allows for non-invasive ease of access
(Birchall, 2007). After more than a decade of research on therapeutic
siRNA delivery, clinical success stories are still sparse and the
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pulmonary route is not an exception (Bobbin and Rossi, 2016). While
engineering dry powders for inhalation from nanoparticle suspensions
containing nucleic acids by spray-drying (Bielski et al., 2017) or spray-
freeze-drying (Okuda et al., 2018) has successfully been described, the
question of a suitable nanocarrier has yet to be answered. While the low
concentration of nucleases in the lung may be advantageous for nucleic
acid administration, the presence of mucus and surfactant poses phy-
sical and chemical barriers, on the other hand, for non-viral carriers of
nucleic acids (Sanders et al., 2009).
Traditionally, liposomes have been amongst the most prevalent
nanocarriers for nucleic acid delivery in the lung. However, lipoplexes
(cationic lipid-based particles, Fig. 7) have gained popularity because
liposome stability is negatively aﬀected by surfactants (Rudolph et al.,
2000; Alton et al., 2013). Unfortunately, lipoplexes bear the potential
for inducing dose-dependent cellular toxicity (Lv et al., 2006; Weber
et al., 2014). Thus, anionic liposomes have been developed for gene
delivery (Lee and Huang, 1996); however, they require the use of ca-
tionic helper molecules such as calcium chloride, poly(amino acid) or
some arginine-rich oligomer to initially compact nucleic acids for en-
capsulation. Another type of nanocarriers that is being evaluated in
clinical trials for other administration routes includes solid lipid na-
noparticles (SLNs), which have higher stability in biological environ-
ments and oﬀer controlled drug release. In addition, they present im-
proved chemical stability of the encapsulated nucleic acids and entail
an inexpensive and scalable production (Mehnert and Mäder, 2001).
Their performance in pulmonary nucleic acid delivery has yet to be
investigated. Two potential hurdles could be their destabilization upon
interacting with lung surfactants or their lack of mobility in mucus
(Sanders et al., 2009).
Polymers as nucleic acid nanocarriers, most importantly suﬀer from
polydispersity concerns that can cause poor reproducibility of a for-
mulation. Cationic polyplexes logically encounter the same toxicity
problems as cationic lipoplexes, while synthetic cationic polymers are
additionally often non-degradable and can be immune-stimulatory
(Beyerle et al., 2011; Merkel et al., 2011; Sanders et al., 2009). In an
approach similar to anionic lipoplexes, PLGA, which is negatively
charged, has been modiﬁed with hydrophilic and cationic polymers,
such as poly(ethylenimine) and chitosan, for electrostatic adsorption of
nucleic acids (Su et al., 2012). However, this kludge neither addresses
the endogenous toxicity of polycations nor the overall rather low en-
capsulation eﬃcacy of nucleic acids in the resulting modiﬁed PLGA
nanoparticles.
One approach that may hold promise, however, is pursued by
combining the advantages of lipid formulations that oﬀer better
monodispersity and a natural endosomal escape mechanism with the
muco-inertness and stability of polymer particles in lung lining ﬂuids.
Core-shell hybrid particles of lipid–PLGA (Fig. 7) have therefore been
especially designed for siRNA delivery (d'Angelo et al., 2018;
Raemdonck et al., 2014). Such hybrid nanoparticles have yet to be
investigated in preclinical and later in clinical settings. Currently, the
main limitation of this approach is their comparably low loading ca-
pacity of nucleic acids, considering that the carrier material is at least
twice as much as in a conventional liposome or polymer particle. An-
other downside to this approach is the more laborious and costly pre-
paration, which follows several steps and may not be easily scalable. In
light of the latest discoveries in genome editing including the CRISPR-
Cas9 technology, eﬃcient formulations for nucleic acids are urgently
needed. While the pulmonary route certainly is only one possible ex-
ample of promising local administration routes, many other routes are
currently being investigated.
5. 3D-printed dosage forms made from lipids and polymers
The processes used to produce tablets, the dominant form of med-
icine taken by patients, have changed relatively little for many years.
Whilst these approaches serve the industry and patients well, they re-
main limited in some clinical areas and moreover, cannot create com-
plex dosage forms or bespoke medications tailored for an individual or
sub-population (i.e. personalized medicines). 3D printing in its many
diﬀerent forms (extrusion, ink-jet, stereolithography, etc.), oﬀers a
possible route to address these issues (Konta et al., 2017). Indeed,
several laboratories around the world have now convincingly demon-
strated that 3D printing may be used to manufacture small batches of
functional medicines that could be expected to be safe for patients and
to pass standard regulatory tests (Norman et al., 2017).
3D printers continue to develop rapidly, and we can expect to see
the quality and speed of production improve signiﬁcantly. To date, a
number of studies have shown that currently approved materials for
pharmaceutical manufacture can be used in various diﬀerent types of
3D printing processes, such as fused deposition modelling (FDM) (Liang
et al., 2018b; Sadia et al., 2018a; Solanki et al., 2018), extrusion
(Khaled et al., 2015a,b), hot-melt ink jet (Kyobula et al., 2017) and
selective laser sintering (Fina et al., 2018; Prasad and Smyth, 2016).
There, nevertheless, remains signiﬁcant material challenges and op-
portunities for the formulation and manufacture of medicines by 3D
printing (and in particular for solvent ink-jet approaches), both for
optimization of properties for printing and achieving new functional-
ities that 3D printing can enable. The consequent need to establish an
expanded pallet of materials suited for 3D printing of medicines in
general, and for ink-jet based methods in particular, is perhaps one of
the most important technical challenges ahead of the ﬁeld.
The most commonly applied 3D printing method for research in
pharmaceutical manufacture is FDM, whereby a pre-formed polymeric
ﬁlament is melted and extruded to form a deﬁned three-dimensional
object on freezing. Many studies have shown the potential of in-
corporating drugs into the polymer ﬁlament (Sadia et al., 2016; Solanki
et al., 2018). FDM work has included a demonstration of the use of
dosage form geometry to control drug release viamanipulation of tablet
surface area and diﬀusion lengths (Goyanes et al., 2015).
It has also been shown that 3D printing via paste-extrusion and ink-
jet methods can be used to produce tablets with novel 3D architecture
and compositions, designed to control drug release and allow perso-
nalization for a given patient. For example, ‘polypill’ tablets have been
printed using an extrusion method that contains the diﬀerent drugs (up
to 5) in separate compartments, each of which can have its release
controlled independently through the use of alternate release mem-
branes or matrices (Khaled et al., 2015a,b). In an alternate strategy, the
geometry and surface area of a tablet may be used to modulate drug
release, as these parameters can be set diﬀerently for every tablet using
3D printing (Kyobula et al., 2017). Notably, polypills have also been
produced using alternative 3D printing approaches such as FDM, once
again indicating the potential for exploiting these diﬀerent routes, and
hence mechanisms of manufacture that this family of approaches oﬀer
(Sadia et al., 2018b).
Until now, the main excipients used in the 3D printing of medicines
have been polymers. For example, 3D-printed dosage forms have been
Fig. 7. Lipid- and polymer-based nanocarriers for pulmonary nucleic acid de-
livery. While lipoplexes consist of cationic lipids and polyplexes of cationic
polymers that electrostatically interact with nucleic acids, lipid polymer hybrid
nanoparticles can be made by lipids encapsulating a polymeric core that con-
tain the nucleic acid load.
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prepared with various commonly employed and approved natural and
synthetic polymeric materials such as PVP, microcrystalline cellulose,
sodium starch glycolate, poly(acrylic acid), PEG and HPMC. These have
primarily been used in formulations of pastes for extrusion 3D printing
(Clark et al., 2017; Khaled et al., 2018; Khaled et al., 2015a,b; Kyobula
et al., 2017) (Fig. 8). For hot-melt ink-jet-based printing, natural waxes
such as beeswax (Kyobula et al., 2017) and candelilla, which have the
appropriate rheological and thermal properties to be printed from the
melt whilst incorporating a thermally stable drug (in much the same
manner as standard HME) have also been exploited. Such natural pro-
ducts can present diﬃculties in terms of reproducibility and adapt-
ability in formulating for 3D printing due to their potential variability
in properties. Currently available pharmaceutical grade lipid-based
materials such as Compritol® (Aburahma and Badr-Eldin, 2014) re-
present viable regulatory approved alternatives with suitable physical
(melting point, rheology) and chemical properties.
Ink-jet printing from a solution or a suspension (as in personal
desktop printers), presents a signiﬁcant formulation challenge in com-
parison to printing from the melt because the solidiﬁcation methodol-
ogies currently employed rarely use safe materials for human con-
sumption. In recent work, high throughput methods to identify new
inks based on a range of properties related to their application were
investigated (Louzao et al., 2018). For example,> 250 new ink for-
mulations in a high-throughput format were assessed for the release of
the drug, paroxetine. The selected candidates with the desirable
properties were scaled up using 3D printing into a range of object ar-
chitectures (Fig. 9) (Louzao et al., 2018).
Another approach, which shows promise for the future on how to
screen for suitable excipient materials, is statistical modelling. When
combined with long-term stability studies it was used to assist for-
mulation selection, and identify the most suitable manufacturing pro-
cess for the preparation of solid dispersions of poorly soluble drugs, as is
typically formed in ink-jet based printing. For example, in a proof-of-
principle study, 60 solid dispersion formulations were produced using
ten chemically diverse, neutral, poorly soluble drugs, three commonly
used polymers, and two manufacturing techniques (spray drying and
melt extrusion). The extensive experimental dataset was used to build
multiple linear regression models to correlate physicochemical prop-
erties of the drug with stability data. These models indicate which
combination of processing method and polymer carrier is most likely to
give a stable solid dispersion (Fridgeirsdottir et al., 2018).
Many challenges remain to be solved before 3D printing can be
applied to the manufacture of solid dosage forms, particularly, in
scalability/business model, quality control, regulatory approval for any
process which devolves the manufacture away from a central facility
towards the patient and in the new constraints it brings to formulation.
A number of excellent extensive reviews address these important issues
that must be addressed if products are to reach patients (Alhnan et al.,
2016; Liang et al., 2018a; Trenﬁeld et al., 2018) that along with this
work, illustrate that there are clear opportunities for 3D printing of
medicines provided the right clinical need can be identiﬁed. In relation
to polymers and lipid- based materials, many familiar requirements
remain (e.g. material properties, stability, safety) with the additional
constraints associated to the 3D printing processes such as suitable ﬂow
in solution, paste or molten, form and ability to retain in solid form a
printed structure with the adequate spatial resolution.
6. Conclusions
Despite centuries of use in human health history, lipids and poly-
mers have not yet unraveled their full potential as pharmaceutical ex-
cipients. Both exhibit great versatility in terms of structures and func-
tionalities and allow formulators to solve complex drug delivery
challenges, whether used individually or in combination with each
other. Nowadays, the physical combination of lipids and polymers is
commonly exploited in the design of traditional and sophisticated do-
sage forms. As discussed above, lipids and their amphiphilic derivatives
can improve the solubilization capacity of polymeric solid dispersions,
allowing higher doses of water-insoluble drugs to be administered.
Similarly, polymers may endow SEDDS with mucus-penetrating prop-
erties, thereby promoting the absorption of poorly bioavailable APIs.
Moreover, recent progress in chemistry and material sciences has al-
lowed the design of lipids and polymers with unique functional char-
acteristics, making them responsive to stimuli (e.g. pH, temperature) or
capable of exerting a biological action (e.g. possible inhibition of P-
Fig. 8. Examples of dosage forms produced by 3D printing (a) Paste extrusion,
(Khaled, et al., 2015a), reproduced with permission from Elsevier, (b) Hot-melt
ink-jet (Kyobula, et al., 2017) demonstrating the ability to produce complex
multi-drug tablets and controlled geometry dosage forms respectively.
Fig. 9. Summary of the high-throughput method for identifying printable inks (Louzao, et al., 2018), reproduced with permission from the American Chemical
Society.
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glycoprotein) (Constantinides and Wasan, 2006). Polymers and lipids
are now often being chemically linked to impart drug delivery systems
with improved or novel features. Aside from the well-established PEG-
phospholipids that, as discussed above, enter in the composition of
long-circulating liposomes, newer polymer-lipid hybrids such as pull-
ulan-cholesterol or alkylated poly(N-isopropylacrylamide) are emer-
ging as alternative solubilizers for lipophilic APIs or as smart self-as-
sembling systems in drug targeting applications (Bertrand et al., 2017;
Morimoto et al., 2013; Yingchoncharoen et al., 2016). With the rapid
evolution of 3D printing technologies, it can be expected that hybrid
polymer-lipid excipients will allow the design of drug delivery systems
with new characteristics and unprecedented control over the drug re-
lease patterns. For drug delivery scientists, polymers and lipids are set
to remain indispensable tools to address the challenges posed by
medicine of tomorrow and the formulation of ever more complex APIs.
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